Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.14962 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Anju Murayama. Beteiligte Einrichtung: School of Medicine, Tohoku University, Sendai City, Japan. Hauptthemen laut MEDLINE: Prescription Drugs, Medicare Part D. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
To investigate the association between industry‐sponsored meal payments and the prescribing patterns of brand‐name colchicines, namely Colcrys and Mitigare, among Medicare beneficiaries in the United States from 2014 to 2021.
Methods
This cross‐sectional study utilized data from the Open Payments Database and Medicare Part D covering the years 2014 to 2021. The study included 54 836 physicians who submitted more than 10 colchicine claims. Exposure was defined as the receipt of one or more industry‐sponsored meals from the manufacturers of Colcrys or Mitigare. The primary outcomes included the likelihood of prescribing Colcrys and Mitigare, as well as the associated number of claims and Medicare expenditures.
Results
Among 54 836 eligible physicians, 44.9% received meal payments from the Colcrys manufacturer, and 8.0% from the Mitigare manufacturer, over the eight‐year study period. The average meal payment value was $14.9 for Colcrys and $15.1 for Mitigare. The receipt of meal payments was significantly associated with an increased likelihood of prescribing Colcrys (odds ratio: 1.24 [95% CI: 1.21–1.27], p < .001) and Mitigare (odds ratio: 3.54 [95% CI: 2.98–4.20], p < .001). Each additional meal payment corresponded with a significant increase in Medicare expenditures: $55.4 (95% CI: $48.3–$62.5, p < .001) for Colcrys and $153.7 (95% CI: $17.7–$289.6, p = .03) for Mitigare. These associations remained consistent across different specialties and genders.
Conclusion
This study reveals that receipt of meal payments from manufacturers of brand‐name colchicine was significantly associated with an increased rate of prescriptions for these brand‐name drugs, leading to higher Medicare expenditures in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tohoku University, Sendai City, Japan.
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Anju Murayama
Zitieren
APA
Murayama, A. (2024). Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14962
Vancouver
Murayama A. Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.14962
BibTeX
@article{Murayama2024,
author = {Murayama, Anju},
title = {Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.14962}
}
EUVIMED